SLFN11 expression correlates with immune microenvironment and predicts prognosis in melanoma.

Front Immunol · 2025 · PMC12497827 · PMID 41058684

Europe PMC DOI

hedged sentences

0.0630

closest p · 1.3× alpha

0.0640

boldest claim

The sentences

borderline significancep=0.063so close (0.05 < p ≤ 0.1)

Borderline significance was observed in GSE22154 (p=0.063) and GSE53118 (p=0.085).

also in 7,017 other papers

showed a trendP = 0.064so close (0.05 < p ≤ 0.1)

These findings were further validated across multiple independent cohorts: the Lauss 2017 CAR-T therapy cohort showed a trend toward improved PFS (P = 0.064), while the Cho 2020 (anti-PD-1/PD-L1, PFS, P = 0.021), IMvigor210 2018 (anti-PD-L1, OS, P = 0.0051), and Nathanson 2017 (anti-CTLA-4, OS, P = 0.04) cohorts consistently confirmed that high SLFN11 expression is associated with favorable prognosis in immunotherapy settings ( Figure 4B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.